Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
Trial Parameters
Brief Summary
Previous study showed that the proportions of hemorrhagic Infarction after intravenous thrombolysis were 24.2% and 32.5% in the control group and the alteplase group, and most of them were asymptomatic. Hemorrhagic Infarction was a part of the natural progression after acute ischemic stroke. Previous study have shown no significant relationship between hemorrhagic Infarction and poor outcome in acute ischemic stroke (AIS) patients. In this study, a randomized controlled trial will be conducted to explore the efficacy and safety of early antiplatelet therapy after hemorrhagic infarction in acute ischemic stroke treated with intravenous thrombolysis.
Eligibility Criteria
Inclusion Criteria: 1. Acute ischemic patients receiving intravenous thrombolysis within 24 hours upon stroke onset 2. Be confirmed as Hemorrhagic Infarction at 24 to 36 hours after intravenous thrombolysis by computerized tomography 3. The patient or family member signed an informed consent Exclusion Criteria: 1. Early use of anticoagulant drugs within 1 week after intravenous thrombolysis; 2. Tirofiban was used after receiving endovascular treatment; 3. Intraoperative stent placement after receiving endovascular treatment; 4. Subarachnoid hemorrhage or ventricular hemorrhage; 5. There are contraindications for aspirin use;